Our management team consists of highly qualified specialist consultants all of whom have senior level experience having held top positions in the pharmaceutical and healthcare industries, enabling us to provide highly specialised advice and guidance on the projects we get involved in.
Find out more about us here...
Ad Rietveld - Founder and Director
- Telephone: +44 (0)7904 222 898
- Email me
Ad has spent most of his professional career in the pricing and reimbursement of pharmaceuticals with positions as a government payer, in consulting and in industry. He is widely seen as one of the foremost experts working in pricing and reimbursement. During his years in consultancy at RJW & partners since 2008 and previously at Cambridge Pharma Consultancy (now part of IMS Health) from 2000, Ad has advised on a wide range of projects in numerous therapeutic areas for many pharmaceutical companies, bringing his experience as a payer to bear in providing comprehensive market access solutions.
Prior to working in consultancy, Ad was Deputy Director of Pharmaceutical Affairs at the Dutch Ministry of Health, responsible for the development and implementation of pharmaceutical cost containment policies, including the development of a reference price system and price controls. He has an in-depth understanding of social health care insurance systems and has acted as a member of international advisory bodies, including the European Commission’s Pharmaceutical Pricing Transparency Committee. He has been closely involved with the World Health Organisation and World Bank in the development of international pharmaceutical policies and has helped develop the pricing and reimbursement systems in Vietnam, Serbia, Romania and Albania, among others.
Ad has a degree in medicine and an MBA from the Rotterdam School of Management.
Neil Johnson - Founder and Director
- Telephone: +44 (0)7904 225 978
- Email me
Neil has spent his career in the pharmaceutical sector and has held senior roles in pricing and market access, both in industry and in consultancy. Prior to founding RJW & Partners in 2008, Neil was Head of Global Pricing & Market Access at AstraZeneca for 8 years, where he pioneered new approaches and organisational responses to the growing challenge of pricing pressure and access restriction. He went to that position after 9 years at Cambridge Pharma Consultancy (now part of IMS Health), where he was responsible for the Market Access and Health Economics teams in Europe and the US. Neil’s in-depth understanding of the requirements facing modern pharmaceutical companies and broad experience in consulting have led to his reputation for delivering solid and innovative solutions to market access challenges.
Before his positions in the pricing and market access field, Neil was in clinical development at Glaxo (now GSK) for 7 years, where he worked on Zantac and managed the global clinical work on reflux disease and NSAID-associated gastropathy.
Neil has a bachelor’s degree in pharmacology and psychology and a PhD in neuroscience.
- Telephone: +44 (0)7943 859 598
- Email me
Chloë joined RJW & partners as a Director in 2009. She has spent her career in the pharmaceutical sector with senior positions in market access and outcomes research consultancy, and management roles in clinical development in the industry. She takes a special interest in the French healthcare system. Prior to joining RJW & partners, Chloë was General Manager of Mapi Values in Lyon, France and sat on the Mapi Values Board for 3 years. In addition to managing the French team, who specialised in patient reported outcomes, she worked with colleagues in the UK and the Netherlands to provide clients with health economics and outcomes research support relevant to market access decision-makers. Chloë previously worked in the Market Access practice at Cambridge Pharma Consultancy (now part of IMS Health) for 8 years, where she first gained her reputation for approaches to demonstrate the clinical and economic value of products and delivering market access projects with tremendous attention to detail.
Chloë’s in-depth understanding of clinical data comes from holding clinical research management positions with EU and US pharmaceutical companies for over 10 years.
Chloë has a BA and PhD in pharmacology from the University of Cambridge and a diploma in health economics from the University of York.
Nicola Robb - Associate Director
Nicola has been working with RJW & partners since 2009. She has over 10 years’ experience in pharmaceutical pricing and reimbursement. She began her career in the pharmaceutical sector as an analyst with Cambridge Pharma Consultancy (now part of IMS Health), where she worked in several business areas. As a consultant, she specialised in pricing, reimbursement and market access strategy and managed projects across a variety of healthcare areas. Nicola gained a broad knowledge of pharmaceutical markets from consulting projects and from working as a writer for Pharma Pricing & Reimbursement and PharmaQuery, the on-line resource for industry on pricing and reimbursement.
Prior to working within the pharmaceutical sector, Nicola began her career at the World Health Organisation and the United Nations Economic Commission for Europe.
At RJW & Partners, Nicola has continued to manage a wide range of pricing and market access projects in many therapy areas using primary and secondary research techniques. Recent project work has focussed on a range of markets from Europe and the US to emerging markets in Eastern Europe and Latin America.
Nicola has an MA in social anthropology and law from the University of Cambridge and a postgraduate diploma in law from the University of East Anglia.
John Spoors - Associate Director
John first joined RJW & partners in 2012. He has 7 years’ experience in the pharmaceutical sector, and has worked in both consultancy and industry. He takes a special interest in Health Technology Assessment and UK policy issues. He started his career at Merck, Sharp and Dohme, where he was responsible for project managing the company’s UK HTA programme for diabetes, HIV and oncology, and assisting with policy and public affairs campaigns. After 2 years at MSD, John joined Helen Johnson Consulting Limited, where he worked for 3 years on HTA and policy projects for leading pharmaceutical companies and patient organisations across a broad range of therapy areas.
At RJW and Partners, John continues to provide expertise on UK HTA and policy issues and received the “Best New Investigator” award for his podium presentation on UK Patient Access Schemes at ISPOR in Berlin in 2012. He has gained experience on European healthcare systems working on a range of international market access projects. John’s skills in planning and managing international payer advisory boards and payer negotiation workshops are particularly valued by our clients.
John has a BA in politics and economics from the University of Manchester, a DipHE in Natural Sciences from the Open University and is currently studying for an MSc in Public Health from the London School of Hygiene and Tropical Medicine.